Sclerotherapy of benign oral vascular lesions with non-diluted ethanolamine oleate / Escleroterapia de lesiones vasculares orales benignas con oleato de etanolamina no diluido

Benign oral vascular lesions are anomalies characterized by the blood vessels proliferation or malformation and the treatment with the sclerosing agent ethanolamine oleate acts irrigating the vessel producing a sterile inflammatory response. The objective of this study was to report and discuss the results from treatment of benign oral vascular lesions with non-diluted ethanolamine oleate through the analysis of clinical records. The sample was composed by the selection of twenty-six patients (12 male and 14 female), with oral vascular malformations. All lesions were treated with intralesional injections of undiluted ethanolamine oleate. These patients attended in Oral Medicine outpatient clinic of the Federal University of Paraná between the years of 2011 to 2015. The average age was 60.65 years, with a higher prevalence for women. The majority of the individuals had one lesion and its location was mostly in the lower lip. The main complaint was about a physical discomfort. The lesions had the average size of 6.52 mm and received a median number of 2.32 applications. Only one patient reported feeling pain in the postoperative week. In most cases the resolution of the lesion was considered partial. Follow-up was obtained up to one month after the end of treatment. The sclerotherapy with undiluted ethanolamine oleate shows acceptable results in the treatment of small benign oral vascular lesions with a few minor side effects.

Las lesiones vasculares orales benignas son anomalías caracterizadas por la proliferación o malformación de los vasos sanguíneos y el tratamiento con el agente esclerosante etanolamina oleato actúa irrigando el vaso produciendo una respuesta inflamatoria estéril. El objetivo de este estudio fue informar y discutir los resultados del tratamiento de lesiones vasculares orales benignas con oleato de etanolamina no diluido a través del análisis de historias clínicas. La muestra estuvo compuesta por la selección de veintiséis pacientes (12 hombres y 14 mujeres), con malformaciones vasculares orales. Todas las lesiones fueron tratadas con inyecciones intralesionales de oleato de etanolamina sin diluir. Estos pacientes acudieron a la clínica ambulatoria de Medicina Oral de la Universidad Federal de Paraná entre los años 2011 a 2015. La edad promedio fue de 60,65 años, con una mayor prevalencia para las mujeres. La mayoría de los individuos tenían una lesión y su ubicación era principalmente en el labio inferior. La queja principal era sobre una molestia física. Las lesiones tenían un tamaño promedio de 6,52 mm y recibieron una mediana de 2,32 aplicaciones. Solo un paciente informó haber sentido dolor en la semana postoperatoria. En la mayoría de los casos, la resolución de la lesión se consideró parcial. El seguimiento se obtuvo hasta un mes después del final del tratamiento. La escleroterapia con oleato de etanolamina sin diluir muestra resultados aceptables en el tratamiento de pequeñas lesiones vasculares orales benignas con algunos efectos secundarios menores.

Dental and oral manifestations of celiac disease.

BACKGROUND: The objective of this study was to evaluate the dental and oral manifestations in patients with celiac disease. MATERIAL AND METHODS: The sample consisted of 40 patients with the disease and 40 without the disease matched by age in southern Brazil. The CD group included patients previously diagnosed by positive anti-endomysial (IgA) examination and confirmed by small intestine biopsy. The presence of dental enamel defects and dental caries was evaluated by a calibrated researcher according to AINE's and WHO's criteria, respectively. The history of recurrent aphthous ulcers and dry mouth was obtained through reporting. For the evaluation of the salivary flow, the saliva samples were obtained through the non-stimulated and stimulated saliva collection method. RESULTS: There was a significant association between CD and dental enamel defects (OR=2.38, P=0.045) and dry mouth (OR=9.15, P=0.002). No difference was found for the report of recurrent aphthous ulcers and caries experience between the two groups. Patients with CD had normal pattern of unstimulated and stimulated saliva flow rates (0.67 ± 0.38 ml / min and 1.14 ± 0.47 ml / min, respectively). A higher occurrence of dental enamel defects was observed in patients with classic CD (P=0.054). Of the 1,962 permanent teeth, 59 presented dental enamel defects, 71.8% of which were in patients with CD (P=0.001), predominantly in molars (P=0.009). CONCLUSIONS: CD increased the likelihood of dental enamel defects and dry mouth sensation. The oral examination can be an important auxiliary tool for the identification of cases of the disease.

Prophylactic therapy with valganciclovir in high-risk (cytomegalovirus D+/R-) kidney transplant recipients: a single-center experience.

BACKGROUND: A prospective study was performed in kidney transplant patients at risk of developing cytomegalovirus (CMV) infection (CMV D+/R-). They were treated with valganciclovir (VGC) for 3 months as prophylactic therapy. The aim was to determine the safety and efficacy of prophylactic therapy with VGC. METHODS: Antigenemia and/or polymerase chain reaction CMV was routinely performed every 2 weeks up to month 3, monthly to month 6, and every other month until the end of the first year posttranplantation, as well as when clinically indicated. RESULTS: From July 2007 to April 2010, 366 renal transplantations were performed at our center, including 34 (9%) high-risk patients for CMV infection. The median age was 47 years; 19 were males and 15 females. Twelve (35%) patients developed CMV infections: 10 (34%) gastrointestinal disease and 3 viral syndromes. The timing of the clinical manifestations was 16% (3/12) between months 1 and 3, 75% (8/12) between months 4 and 6, and 8% (1/12) in month 9 posttransplantation. CONCLUSION: Treatment with intravenous ganciclovir followed by oral VGC was successful in all patients. No opportunistic infections or allograft rejection were observed; only 1 patient developed thrombocytopenia as an adverse event to VGC.

[Herpes simplex virus encephalitis in a renal transplant patient]. / Encefalitis por virus herpes simple en paciente portadora de trasplante renal. Estudio de un caso y revisión de la literatura.

The incidence of herpes simplex virus (HSV) encephalitis is estimated to occur annually in 2-4 cases per million population. HSV encephalitis is exceptional in renal transplant patients, we have found two previous reports after an extensive bibliography search. We report a case of a 47 years old women renal transplant recipient who presented 3 months after transplantation fever, stupor and aphasia. The diagnosis HSV encephalitis was achieved by PCR in cerebrospinal fluid and magnetic resonance imaging. She was treated with aciclovir for 4 weeks and recovered completely without neurologic sequelae.

Encefalitis por virus herpes simple en paciente portadora de trasplante renal. Estudio de un caso y revisión de la literatura / Herpes simplex virus encephalitis in a renal transplant patient

La incidencia estimada de encefalitis por virus herpes simple (VHS) es de 2-4casos anuales por millón de población general. La encefalitis por VHS en pacientestrasplantados es una complicación muy poco frecuente, de la que sólo hemosencontrado dos citas en la revisión bibliográfica realizada.Presentamos el caso de una paciente de 47 años que a los 3 meses del trasplanterenal presentó un cuadro de fiebre, estupor y afasia debido a una encefalitispor VHS. El diagnóstico se realizó mediante PCR en líquido cefalorraquídeoy resonancia magnética cerebral. La paciente fue tratada con aciclovir, recuperándosesin secuelas clínicas

The incidence of herpes simplex virus (HSV) encephalitis is estimated to occurannually in 2-4 cases per million population. HSV encephalitis is exceptional inrenal transplant patients, we have found two previous reports after an extensivebibliography search.We report a case of a 47 years old women renal transplant recipient who presented3 months after transplantation fever, stupor and aphasia. The diagnosis HSVencephalitis was achieved by PCR in cerebrospinal fluid and magnetic resonanceimaging. She was treated with aciclovir for 4 weeks and recovered completely withoutneurologic sequelae

Nefrología basada en investigación clínica: bases conceptuales para la constitución de un grupo de trabajo en Nefrología Basada en la Evidencia de la Sociedad Española de Nefrología / No disponible

No disponible

Encefalitis por virus herpes simple en paciente portadora de trasplante renal. Estudio de un caso y revisión de la literatura / Herpes simplex virus encephalitis in a renal transplant patient

La incidencia estimada de encefalitis por virus herpes simple (VHS) es de 2-4casos anuales por millón de población general. La encefalitis por VHS en pacientestrasplantados es una complicación muy poco frecuente, de la que sólo hemosencontrado dos citas en la revisión bibliográfica realizada.Presentamos el caso de una paciente de 47 años que a los 3 meses del trasplanterenal presentó un cuadro de fiebre, estupor y afasia debido a una encefalitispor VHS. El diagnóstico se realizó mediante PCR en líquido cefalorraquídeoy resonancia magnética cerebral. La paciente fue tratada con aciclovir, recuperándosesin secuelas clínicas

The incidence of herpes simplex virus (HSV) encephalitis is estimated to occurannually in 2-4 cases per million population. HSV encephalitis is exceptional inrenal transplant patients, we have found two previous reports after an extensivebibliography search.We report a case of a 47 years old women renal transplant recipient who presented3 months after transplantation fever, stupor and aphasia. The diagnosis HSVencephalitis was achieved by PCR in cerebrospinal fluid and magnetic resonanceimaging. She was treated with aciclovir for 4 weeks and recovered completely withoutneurologic sequelae

Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine.

To evaluate the efficacy and safety of conversion from cyclosporine to tacrolimus, we analyzed 55 kidney transplant patients who were converted due to cosmetic reasons in 42 patients, acute rejection in 2 patients, and other causes in 11 patients. At the doses and levels used, the development of diabetes mellitus was minimized. Disappearance of cosmetic side-effects and improvement of cardiovascular risk factors, together with conservation of renal function, encourage us to use tacrolimus as an efficacious and safe immunosuppressive therapy.

Case Reports. Infection due to Scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by Pseudallescheria boydii/Sc. apiospermum.

Two cases of infections due to Scedosporium apiospermum in renal transplant recipients, one localized in the central nervous system, the other in the skin, are presented, and a literature review of 21 cases of central nervous system and cutaneous infections due to Pseudallescheria boydii/Sc. apiospermum is given.

Registros sanitarios, una necesidad actual / The need of sanitary registries

No disponible

Informe de diálisis y trasplante de la sociedad española de nefrología y registros autonómicos correspondientes al año 1999 / Dyalisis and transplant registry of the Spanish Society of Nephrology

No disponible